PLEASE NOTE: This is a working agenda. Check back for updates and announcements!
A BIG THANK YOU TO THE ALLICENSE CONTENT ADVISORY BOARD
The work which the Allicense Planning Council has contributed is invaluable to the success of Allicense.
The Allicense Planning Council has devoted invaluable effort to the success of Allicense. Their time, energy and contributions are what make Allicense the unparalleled forum for dealmaking it is known for.
15 min Conference Wrap Up: Laura Vitez, Principal Business
Analyst, Thomson Reuters
8:00-8:15 AM Conference Kick Off: Let’s Play Chess!
Presented by Peter Kolchinsky, PhD, Managing Director and Portfolio Manager, RA Capital Management LLC
Mapping the chessboard: the competitive game theory that governs how companies can, should, and yet only sometimes do, assimilate all the necessary new technologies to grow and defend against disruption. Where are the unmet needs, what are the opportunities, and who should be talking to whom, from the perspective of an evidence- based crossover investor.
8:45-9:45 AM Panel Discussion: At What Price? Drug Pricing Clarity and Solutions
Presented by James C. Robinson, PhD, MPH, Leonard D. Schaeffer Professor of Health Economics, University of California at Berkeley
Though drug cost-valuation debates aren't new, the battle exploded onto a global center stage in 2015 when a previously little-known CEO unapologetically hiked the price of an in-licensed generic drug 5500%. Simultaneously patients’ voices have grown louder, especially given increased consumer cost sharing. In the U.S., the pending presidential election gives politicians more ammunition than ever to enact price regulations that could have an enormous impact on innovation. It’s a perfect storm. As public criticism grows, rather than rehashing old arguments, experts are gathering at Allicense for a candid discussion providing fresh clarity and proposing a variety of pro-active, granular, workable solutions to the ongoing drug pricing controversies.
10:30-11:30 AM Investing and Exiting and Doing It Again: Private, Crossover, and Public Strategies
Presented by Jonathan Norris, JD,
Managing Director, Silicon Valley Bank
What are the current trends in financing and exits for venture-backed biopharma companies? Where are the active investors deploying their capital? What is the role of crossover investors in 2016? Has the influence of the ever-changing public market changed VC’s underlying investment theses? Will the IPO window continue in 2016? Is early stage M&A a long term trend for the industry?
1:30-2:15 PM Panel Discussion: Fostering and Transferring Innovation: Working Together to keep the Ecosystem Healthy
Presented by David Dunn, PhD, Practice Lead, Portfolio and Licensing Professional Services, Thomson Reuters
Industry has always relied upon ground-breaking discoveries originating from academic and other early-stage research. These discoveries range from new insight into disease mechanisms and potential novel therapeutic points of intervention, through inventive therapeutic approaches to unmet medical needs and their validation in the clinic. There are great opportunities at the interface between academia and commercial enterprise; yet there are also multiple challenges. Issues include the negotiation of rights of ownership, financial terms, management of joint research efforts, and transfer of knowledge. This panel will pull together industry and academia veterans who have navigated the challenges of translating discoveries into commercial opportunities.
Presented by Karl Handelsman, Founder, Codon Capital
Our panel of serial "value creators" will describe their approach to building companies through BD. Many key decisions open up the ability to rapidly create breakthrough innovations: collaborate or control, build or partner, financing pathways, best practices of engaging with Universities, KOLs, Pharma. In addition to a group experience moving from early startup to IPO, we will discuss how the dealmaking ecosystem will continue to evolve.